4//SEC Filing
Oltmans Curtis Gale 4
Accession 0001562180-19-000564
CIK 0001100412other
Filed
Jan 28, 7:00 PM ET
Accepted
Jan 29, 4:27 PM ET
Size
10.9 KB
Accession
0001562180-19-000564
Insider Transaction Report
Form 4
Oltmans Curtis Gale
General Counsel
Transactions
- Exercise/Conversion
Common Stock
2019-01-25$8.94/sh+14,029$125,419→ 17,950 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-01-25−14,029→ 415,000 totalExercise: $8.94Exp: 2027-08-15→ Common Stock (14,029 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2019-01-29−11,100→ 403,900 totalExercise: $8.94Exp: 2027-08-15→ Common Stock (11,100 underlying) - Sale
Common Stock
2019-01-25$18.00/sh−14,029$252,523→ 3,921 total
Footnotes (3)
- [F1]These trades were made pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported for these shares is the weighted average sale price of transactions made at prices from $18.00 to $18.001. Details of actual prices for shares sold are available from the Issuer upon request.
- [F3]The option vests in four equal annual installments beginning August 15, 2018.
Documents
Issuer
ARRAY BIOPHARMA INC
CIK 0001100412
Entity typeother
Related Parties
1- filerCIK 0001714982
Filing Metadata
- Form type
- 4
- Filed
- Jan 28, 7:00 PM ET
- Accepted
- Jan 29, 4:27 PM ET
- Size
- 10.9 KB